期刊
MODERN RHEUMATOLOGY
卷 28, 期 5, 页码 789-799出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14397595.2017.1416940
关键词
Low disease activity; rheumatoid arthritis; remission; residual symptom; systematic literature review
类别
资金
- Tanabe Mitsubishi Pharma
- AbbVie
- Bristol-Myers K.K.
- Eisai
- UCB
- Pfizer Japan
- Takeda Pharmaceutical
- Eli Lilly
- Astellas Pharma
- Chugai Pharmaceutical
- Kyowa Hakko Kirin
- TaishoToyama
- Janssen
- EA Pharma
- Ayumi Pharmaseutical
- Eli Lilly Japan K.K
Objectives: To identify, describe and summarize evidence on residual symptoms and disease burdens in rheumatoid arthritis (RA) patients qualified as being in remission or low disease activity (LDA).Methods: A systematic literature review (SLR) was conducted according to Cochrane collaboration guidelines. The population of interest was adult patients with RA in remission or LDA. The reported outcomes of interest were any symptoms or burdens.Results: Fifty-one publications were identified through an eDatabase search. Together with 17 articles found through other sources, 68 were included for full text review. The most commonly reported residual symptoms were pain (number of studies=25), fatigue (n=21) and morning stiffness (n=5). Reported disease burdens included mental health (n=15), sleep disturbances (n=7) and work productivity (n=5), impairment in quality of life (n=21), and functional disability (n=34). Substantial residual symptoms and disease burdens were found to be present in patients in remission or LDA.Conclusion: This is the first SLR to investigate residual symptoms and disease burdens in RA patients in remission or LDA. The results indicate that despite achieving conventional clinical targets, the disease continues to affect patients, suggesting the existence of unmet need under the current treatment paradigm.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据